COMPANY:

Sophia Genetics

"SOPHiA GENETICS...announced the global launch of MSK-IMPACT® powered with SOPHiA DDM™ today from the Association for Molecular Pathology (AMP) Annual Meeting. This innovative solution provides organizations worldwide with the opportunity to benefit from Memorial Sloan Kettering Cancer Center (MSK)’s best-in-class comprehensive genomic profiling (CGP) application on the SOPHiA DDM™ Platform with high accuracy and efficiency...The launch of MSK-IMPACT® powered with SOPHiA DDM™ is another major milestone in our journey to expand access to precision oncology globally and demonstrates our commitment to democratizing data-driven medicine"

"SOPHiA GENETICS...will be presenting multiple posters at the European Society for Medical Oncology (ESMO) Congress 2024 being held in Barcelona, Spain September 13-17, 2024. The ESMO Congress is a globally influential oncology platform for clinicians, researchers, patient advocates, journalists and healthcare industry representatives from all over the world."

"SOPHiA GENETICS...announced an update that several world-renowned healthcare organizations have joined SOPHiA UNITY. SOPHiA UNITY...at ASCO by SOPHiA GENETICS that connects best-in-class healthcare institutions to fuel the next wave of innovation in oncology by making real-world data available for research."

"SOPHiA GENETICS...announced that the company is joining the European Liquid Biopsy Society (ELBS), a prestigious network consisting of partners from academia and industry with the common goal of making liquid biopsy tests part of the routine standard of care...The ELBS primarily focuses on liquid biopsy testing for cancer, which aligns with the work that SOPHiA GENETICS has done to increase access to this sophisticated testing. SOPHiA GENETICS decentralized MSK-ACCESS®, the highly validated ctDNA assay developed by Memorial Sloan Kettering Cancer Center (MSK), so customers in Europe and worldwide have access to a best-in-class liquid biopsy solution."

"SOPHiA GENETICS...announced a new milestone in the global introduction of the liquid biopsy test MSK-ACCESS powered with SOPHiA DDM, first announced in October 2023. Under a definitive partnership agreement with AstraZeneca...SOPHiA GENETICS will accelerate the deployment of MSK-ACCESS powered with SOPHiA DDM to 20 locations worldwide over the next 12 months...The testing works by isolating cell-free DNA (cfDNA) from blood plasma to uncover circulating tumor DNA (ctDNA)...The partnership with AstraZeneca will further catalyze the adoption of MSK-ACCESS powered with SOPHiA DDM....As more hospitals and labs go into routine, SOPHiA GENETICS and AstraZeneca, in collaboration with leading cancer institutes within the SOPHiA GENETICS community, will generate a vast set of real-world data from patients around the world with a variety of cancers. This data set has the potential to generate unique insights towards advancing cancer research and drug development."

"SOPHiA GENETICS...launched the new generation of the SOPHiA DDM™ Platform. The new-gen SOPHiA DDM™ Platform offers a new architecture designed to more efficiently compute large amounts of data at-scale, while elevating customer experience with integrated access to multimodal analytics modules."

"SOPHiA GENETICS...announced that its SOPHiA DDM™ Platform is now CE marked under the European Union's In Vitro Diagnostic Regulation (IVDR). IVDR certification is a significant regulatory milestone that validates the powerful analytical capabilities of the SOPHiA DDM™ Platform and allows customers throughout the European Union and other markets recognizing this certification to use the SOPHiA DDM™ Platform to support patient diagnostics."

"SOPHiA GENETICS...announced that L'hôpital Universitaire Avicenne is implementing the SOPHiA DDM™ Platform. The hospital, located in Bobigny, France, will use the platform to advance its testing and research of blood-related cancers and disorders."

"SOPHiA GENETICS...announced...that OncoHelix...will implement MSK-ACCESS® powered with SOPHiA DDM™. The organization, which currently uses the SOPHiA DDM™ Platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities. OncoHelix will be live on MSK-ACCESS® powered with SOPHiA DDM™ later this summer."

"SOPHiA GENETICS...announced that Dhiti Omics Technologies...is live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETICS’ technology to enhance its solid tumor testing capabilities...By implementing SOPHiA DDM™ for the Agilent SureSelect Cancer CGP application, Dhiti Omics will improve its ability to provide researchers actionable information on mutations and biomarkers across hundreds of genes."

"SOPHiA GENETICS...announced its new Residual Acute Myeloid (RAM) Application. The new offering expands the company’s comprehensive oncology portfolio to support measurable residual disease (MRD) capabilities and will be available to customers worldwide this summer."

"SOPHiA GENETICS...announced...that the IUCT-Oncopole (called 'Oncopole'), a comprehensive cancer center in Toulouse, France, has expanded its research and testing abilities with the implementation of MSK-ACCESS® powered with SOPHiA DDM™. Clinicians at Oncopole will use the liquid biopsy testing capabilities to conduct non-invasive cancer genomic profiling and monitoring for patients."

"SOPHiA GENETICS...announced that Kepler Uniklinikum...is live on SOPHiA GENETICS' platform. The hospital will use the SOPHiA DDM™ Platform to advance its next-generation sequencing (NGS) testing and diagnostics of blood-related cancers."

"SOPHiA GENETICS...announced that it is collaborating with Microsoft and NVIDIA to leverage their expertise in technology and genomics to bring a streamlined and scalable whole genome sequencing (WGS) analytical solution to healthcare institutions, with the aim to make the solution available to customers before the end of the year."

"SOPHiA GENETICS...announced that Instituto Mário Penna is live on the SOPHiA DDM™ Platform. Located in Belo Horizonte, Brazil, the Instituto Mário Penna will use SOPHiA GENETICS' technology to advance its testing, research, and advance data-driven diagnoses and treatment decisions for blood-related cancers and disorders."

"SOPHiA GENETICS...announced that Klinikum Klagenfurt am Wörthersee...is live on the SOPHiA DDM™ Platform. The hospital will use SOPHiA GENETICS' technology to enhance its next-generation sequencing (NGS) testing and deepen its analytical capabilities for solid tumor and blood cancer (hematology oncology) samples."

"SOPHiA GENETICS...announced that Nigeria-based Syndicate Bio has signed on to implement MSK-ACCESS® powered with SOPHiA DDM™. Syndicate Bio is the first lab in Africa to adopt the MSK-ACCESS® assay via the SOPHiA DDM™ Platform, and the first company to make comprehensive genomic profiling and liquid biopsy widely available to patients throughout the entire continent. The implementation of this new technology will further existing work from SOPHiA GENETICS, Memorial Sloan Kettering Cancer Center (MSK), and Syndicate Bio to advance health equity on a global scale."

"SOPHiA GENETICS...announced that Unilabs...is live on the SOPHiA DDM™ Platform. Unilabs will use SOPHiA GENETICS' technology to test for HRD-status in solid tumors and provide expedited analysis across its network in Switzerland."

"SOPHiA GENETICS...announced a strategic partnership with Strand Life Sciences...to deliver innovative solutions that will fuel the use of precision medicine globally. The new collaboration will leverage the industry-leading strengths from both companies to provide access to advanced genomics technologies, cutting-edge bioinformatics services and innovative diagnostics solutions."

“SOPHiA GENETICS…announced that Laboratorio Barnafi-Krause is live on the SOPHiA DDM™ Platform. Laboratorio Barnafi-Krause, located in Chile, has implemented SOPHiA GENETICS' technology to help elevate its testing and analysis of blood cancers and diseases, including Leukemia.”

"SOPHiA GENETICS...announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM™ Platform for use in its cutting-edge clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing. This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing."

"SOPHiA GENETICS...and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal algorithm to help predict post-operative outcomes for those facing renal cell carcinoma (RCC), with the results recently published in npj Precision Oncology. The findings of the study showed the artificial intelligence (AI) model co-constructed by SOPHiA GENETICS and UroCCR provided a strong prediction for post-operative outcomes when compared to usual prognostic scores. This publication follows a prior collaboration that demonstrated the value of multimodal analysis on pre-operative kidney cancer upstaging."

"SOPHiA GENETICS...announced that Universidad de Costa Rica El Centro de Investigación en Cirugía y Cáncer (CICICA) is now live on the SOPHiA DDM™ Platform. The Surgery and Cancer Research Center is using SOPHiA GENETICS to expand its ability to trace, diagnose, and treat rare and inherited diseases among Costa Ricans."

"SOPHiA GENETICS...announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD) throughout the country. The expansion of the program, supported by AstraZeneca Spain and its network throughout the country, will further SOPHiA GENETICS' commitment to global health equity by making this vital testing available to thousands more patients in the country....With today's announcement, AstraZeneca Spain named SOPHiA GENETICS its preferred partner in deploying HRD testing throughout Spain."

"SOPHiA GENETICS...announced that Medicinski fakultet Univerziteta u Beogradu is live on the SOPHiA DDM™ Platform. The University, which is located in the capital city of Serbia, will use SOPHiA GENETICS’ technology, particularly the hematology-oncology application, to support the enhanced and accurate analysis of lymphoid neoplasms, which are the most common type of blood cancer affecting more than 100,000 people."

"SOPHiA GENETICS...announced that Bioma4me...is now live on the SOPHiA DDM™ Platform. The company will use SOPHiA GENETICS’ technology to advance and streamline its genetic testing capabilities...Through the SOPHiA DDM™ Platform, Bioma4me will be able to apply its next generation sequencing (NGS) expertise to the whole exome."

"SOPHiA GENETICS...announced that RareCyte Inc...is live on SOPHiA GENETICS. RareCyte has implemented the SOPHiA DDM™ Platform to complement its Precision Biology Services portfolio...The SOPHiA GENETICS technology will help RareCyte's team of scientists and engineers as they continue to develop next-generation products and services that advance precision medicine and biomedical research."

"SOPHiA GENETICS...announced that Karkinos Healthcare...will partner with SOPHiA GENETICS and adopt the SOPHiA DDM™ Platform to advance cancer testing and research for blood cancers and solid tumors to underserved areas in low and middle-income countries."

"SOPHiA GENETICS...announced a collaboration with Exactis Innovation, based in Montreal, Quebec, who will contribute to cancer research and data-driven decision-making through SOPHiA GENETICS’ multimodal real-world data offering...Exactis will join the SOPHiA DDM™ network and leverage the SOPHiA DDM™ platform to access global real-world data insights from multimodal datasets. By joining the SOPHiA DDM™ network, Exactis researchers will access to a global network of data that will provide robust, diverse insights to help support research for its Canadian population."

"SOPHiA GENETICS...announced that OmiCure®...is live on the SOPHiA DDM™ Platform. OmiCure, which works to expand the use of data-driven medicine via its tumor profiling tests, will use SOPHiA GENETICS’ technology to enhance its offerings in support of physicians and patients."

"SOPHiA GENETICS...announced that Hôpital Saint-Louis, located in Paris, has implemented the SOPHiA DDM™ Platform to help advance its research of Myeloid Disorders and continue expanding the use of precision medicine for those in the area. This latest implementation is an expansion of its existing work with SOPHiA GENETICS."

"SOPHiA GENETICS...announced an expanded suite of solutions under SOPHiA DDM™ for Liquid Biopsy. The range of solutions, including MSK-ACCESS® powered with SOPHiA DDM™ and custom solutions, will help progress oncology research and tumor mutation profiling. The rollout of SOPHiA GENETICS' liquid biopsy capabilities demonstrates the company's commitment to developing advanced solutions that empower timely, critical decision-making and improve health outcomes."

"SOPHiA GENETICS...announced that it has expanded its work with CHU de Nîmes, a regional and university hospital located in the South of France. The hospital system will use the SOPHiA DDM™ Platform to progress its pharmacogenomics research."

"SOPHiA GENETICS...announced the expansion of its relationship with the Città della Salute e della Scienza di Torino located in Turin, Italy. The hospital, which used SOPHiA GENETICS after a public tender in 2021 to optimize workflows and support research in the areas of hereditary cancer, neurological disorders, solid tumors, hematology and rare disease, will further expand its usage of the SOPHiA DDM™ Platform to support research on homologous recombination repair (HRR) biomarkers that indicate treatment options for ovarian, prostate, breast and pancreatic cancers."

"SOPHiA GENETICS...announced that the German company OnkoMedeor Diagnostics MVZ GmbH is now live on the SOPHiA DDM™ Platform. OnkoMedeor Diagnostics MVZ GmbH, which is a haematological lab and part of the Haematological Center Dachau (HAEZ) certified by the German Cancer Society (DKG), handles the diagnosis and treatment of blood and tumor diseases and will use SOPHiA GENETICS’ technology to expand its offerings, advance research and streamline workflow."

"SOPHiA GENETICS...announced that BioReference® Health, LLC...will implement SOPHiA GENETICS’ technology and add MSK-ACCESS® liquid biopsy to its test suite. With the implementation of SOPHiA GENETICS, BioReference will be the first laboratory globally to adopt MSK-ACCESS® powered with SOPHiA DDM™. The offering will be commercially available for ordering by healthcare providers through BioReference, and its specialty division, GenPath® Oncology in 2024."

"SOPHiA GENETICS...announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK), a top cancer treatment and research institution, and AstraZeneca...to bring high quality, comprehensive cancer testing to a global scale. With this collaboration, the three leading organizations will further their shared goal to advance health equity on a global scale by providing inclusive access to comprehensive cancer testing worldwide....The partnership will provide MSK's proprietary liquid biopsy and solid tumor cancer tests – MSK-ACCESS^® and MSK-IMPACT^® – to organizations via the decentralized, technology-agnostic SOPHiA DDM™ Platform. This offering will be rapidly deployed by SOPHiA GENETICS with support from AstraZeneca's global footprint."

"SOPHiA GENETICS...announced that Shaare Zedek...is now live on the SOPHiA DDM™ Platform. The Platform will enable Shaare Zedek to advance its insights the treatment of myeloid disorders and further develop the application of precision medicine...With the SOPHiA DDM™ Platform, Shaare Zedek Medical Center will retain complete ownership of its database, supporting the research team as it continues to increase its expertise."

"SOPHiA GENETICS...has expanded its relationship with Laboratorio Curie...Laboratorio Curie is now live on the SOPHiA DDM™ Platform and will use the technology to deploy a new test that will identify BRCA gene mutations. Discoveries made using this test aim to enable Laboratorio Curie to support the increased use of precision medicine for hereditary cancers within the country."

"SOPHiA GENETICS...announced that the IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', an oncology center in Italy, is using the SOPHiA DDM™ Platform to power a new genomic test that will be used to aid physicians in developing personalized treatment plans for those with advanced ovarian cancer...With use of the SOPHiA DDM™ Platform, the test will help identify patients with a homologous recombination deficiency (HRD), which is caused by a cell's impaired ability to repair DNA double-stranded breaks."

"SOPHiA GENETICS...announced that CHU Bordeaux...has completed implementation of the SOPHiA DDM™ Platform into its organization. The hospital will be using the SOPHiA GENETICS technology to help advance its research on homologous recombination repair (HRR) mutated cancers."

"SOPHiA GENETICS...announced the expansion of its relationship with Gustave Roussy, the leading cancer center in Europe. With the expanded relationship SOPHiA GENETICS will now further support Gustave Roussy via the SOPHiA DDM™ Platform, which will provide expedited analysis and insights of genomic profiles...Gustave Roussy will now utilize the SOPHiA DDM™ Platform for all relevant samples, including those related to solid tumors, hematologic and hereditary cancers."